Kelun-Biotech Wins Strong Shareholder Backing for 2026 Connected Deals and New Share Incentive Plan

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) just unveiled an update.

At an extraordinary general meeting held on 31 December 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. secured strong shareholder backing for a series of connected transactions and a new equity incentive plan, signaling continued support for its operational and strategic direction. Shareholders overwhelmingly approved three 2026 framework agreements covering promotional services, auxiliary R&D services, and the procurement and sale of equipment and materials, providing a formal basis for ongoing related-party transactions that underpin the company’s commercial and research activities. In addition, investors passed special resolutions to adopt a 2025 Share Incentive Scheme and set its mandate limit at 3.5 million H shares, a move aimed at aligning management and employee interests with long-term shareholder value and reinforcing the company’s competitiveness in attracting and retaining talent in the biopharmaceutical sector.

The most recent analyst rating on (HK:6990) stock is a Buy with a HK$545.00 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.

More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a China-based biopharmaceutical company listed in Hong Kong, focused on the research, development and commercialization of pharmaceutical and biotech products. The company operates within the broader healthcare and life sciences sector, leveraging R&D capabilities and collaborations to support its growth in domestic and international markets.

Average Trading Volume: 619,771

Technical Sentiment Signal: Buy

Current Market Cap: HK$94.63B

Find detailed analytics on 6990 stock on TipRanks’ Stock Analysis page.